Aevum Zenth's immunotherapy platform leverages AI-driven target discovery, next-generation cellular engineering, and mRNA technologies to treat oncology, autoimmunity, and rare genetic disorders.
A unified R&D ecosystem designed to accelerate discovery, reduce attrition, and deliver clinically transformative therapies.
Proprietary machine learning models analyze multi-omic datasets to identify novel immune checkpoints, tumor antigens, and biomarker signatures with 94% predictive accuracy.
Next-gen CAR-T, CAR-NK, and TCR-T platforms featuring optimized scFv binders, safety switches, and allogeneic off-the-shelf manufacturing capabilities.
LNP-delivered mRNA platforms enabling rapid antigen expression, neoantigen vaccines, and precise modulation of cytokine signaling pathways.
From approved treatments to late-stage candidates across complex disease states.
PD-1/LAG-3 bispecific antibody for advanced solid tumors and hematological malignancies.
Third-generation CD19/CD22 dual-targeting CAR-T for relapsed/refractory B-cell lymphomas.
IL-23 pathway inhibitor with enhanced tissue penetration for plaque psoriasis and Crohn's disease.
Personalized neoantigen vaccine platform for high-risk recurrence prevention in rare sarcomas.
Engineered HSV-1 expressing GM-CSF and IL-12 for intratumoral injection in pancreatic adenocarcinoma.
CD3/BCMA bispecific T-cell engager for multiple myeloma with reduced cytokine release syndrome risk.
Transparent tracking of our lead assets from discovery through regulatory submission.
| Asset Code | Modality | Indication | Phase | Progress |
|---|---|---|---|---|
| AZ-4091 | Bispecific Antibody | Solid Tumors | Commercial | |
| Zentecel-A | CAR-T Cell | Non-Hodgkin Lymphoma | Phase III | |
| AZ-2284 | Monoclonal Antibody | Autoimmune Disorders | Phase III | |
| ZenthGene-RT | mRNA Vaccine | Rare Sarcomas | Phase II | |
| AZ-1150 | Oncolytic Virus | Pancreatic Cancer | Phase II |
Vertically integrated production ensuring scale, sterility, and rapid global deployment.
120,000 ft² sterile fill-finish facility for monoclonal antibodies and bispecifics.
Automated CAR-T/NK processing with 48-hour turnaround and closed-system manufacturing.
Rapid prototyping and scale-up for nucleic acid therapeutics and vaccines.
Cold-chain logistics across 6 continents with real-time temperature monitoring.
Whether you're a clinical investigator, biotech partner, or healthcare institution, explore how our immunotherapy platform can advance patient outcomes.